
Freenome fell 22.4% from $13.01 to $10.09, behind the S&P 500's −1.1%. Its worst day was Oct 12 (−16.2%), and its low came Jul 30 at $9.99.
Jul 21, 2026 – Nov 16, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Freenome closed at its lowest level of the year, 23.2% below where the year started.
−0.7% · S&P 500 +1.7%
Freenome shares rose 12.5%, while the S&P 500 fell 0.5%.
Story events cover the past 12 months · Times ET
+12.5%, the year's best day · S&P 500 −0.5%
Freenome closed at its highest level of the year, 31.5% above where the year started.
+5.0%, on 6M shares, the year's heaviest volume · S&P 500 +0.1%
Freenome shares fell 16.2%, while the S&P 500 fell 0.1%.
−16.2%, the year's worst day · S&P 500 −0.1%
– Personalized Cancer Detection provides flexible approach to cover multiple types of cancer screening in a single blood draw –– In an independent cohort, SimpleScreen Lung showed 85% sensitivity at 50% specificity and
+11.9% · S&P 500 +0.3%
EPS of $1.10 beat the $-0.20 estimate on $183.5M revenue (est. $84.9M); FY revenue guidance of $192.0M–$194.0M against the $102.4M consensus.
+7.3% · S&P 500 +1.3%
Where it ended: a close of $10.09 on Nov 16, 2026. Up next: Q4 2026 earnings on Feb 27, 2027 (EPS est. $0.09, revenue est. $84.9M).
Nothing in the past 12 months.
All FRNM dividend historyReplay the year: the line draws itself and stops at each of the 6 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for FRNM and SPY from Benzinga historical bars. Not investment advice.